#1 Clinical Trials Search in Europe

Elraglusib

Elraglusib, also known as 9-ING-41, is an investigational drug being studied for the treatment of various types of cancer, including blood cancers and solid tumors. This article explores the ongoing clinical trials of Elraglusib, focusing on its potential benefits for patients with refractory (hard-to-treat) cancers and its use alone or in combination with other chemotherapy drugs.

Table of Contents

What is ELRAGLUSIB?

ELRAGLUSIB, also known as 9-ING-41, is an investigational drug being studied for the treatment of various types of cancer[1]. It is currently being tested in clinical trials to evaluate its effectiveness and safety in patients with refractory blood cancers (cancers of the blood that have not responded to previous treatments) and solid tumors (cancers that form solid masses in the body)[1].

How Does ELRAGLUSIB Work?

ELRAGLUSIB is a type of drug called a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor[1]. GSK-3β is an enzyme that plays a role in various cellular processes, including cell growth and division. By inhibiting this enzyme, ELRAGLUSIB may help to slow down or stop the growth of cancer cells.

What Conditions Does ELRAGLUSIB Treat?

ELRAGLUSIB is being studied for the treatment of several types of cancer, including:

  • Refractory hematologic malignancies: These are blood cancers that have not responded to previous treatments or have come back after treatment[1].
  • Solid tumors: These include various types of cancer that form solid masses in the body, such as pancreatic cancer[1].

In particular, the current clinical trial is focusing on patients with metastatic pancreatic cancer who have not been previously treated with systemic therapies for advanced disease[1].

Clinical Trial Details

The ongoing clinical trial for ELRAGLUSIB is called “Actuate 1801” and is a combined Phase 1/2 study[1]. This means it will evaluate both the safety and effectiveness of the drug. The study has two main parts:

  1. Testing ELRAGLUSIB as a single agent (by itself)
  2. Testing ELRAGLUSIB in combination with other chemotherapy drugs, specifically gemcitabine and nab-paclitaxel for pancreatic cancer patients[1]

The main goal of the study is to determine the one-year survival rate of patients treated with ELRAGLUSIB compared to a control group[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key eligibility requirements include:

  • Being 18 years of age or older[1]
  • Having confirmed metastatic pancreatic cancer that has not been previously treated with systemic therapies[1]
  • Having at least one measurable tumor lesion[1]
  • Having adequate bone marrow, liver, and kidney function[1]
  • Having an ECOG performance status of 0 or 1 (able to perform most daily activities)[1]

There are also several exclusion criteria, such as being pregnant or breastfeeding, having certain heart conditions, or having rapidly progressing brain metastases[1].

Potential Benefits

While the effectiveness of ELRAGLUSIB is still being studied, the researchers hope to see several potential benefits, including:

  • Improved survival rates for patients with advanced pancreatic cancer[1]
  • Better control of cancer growth and spread (disease control rate)[1]
  • Tumor shrinkage (objective response rate)[1]
  • Longer time before the cancer progresses (progression-free survival)[1]

Safety Considerations

As with any investigational drug, there may be risks and side effects associated with ELRAGLUSIB. The clinical trial will closely monitor patients for any adverse events, using standardized criteria to assess their severity[1]. Patients considering participation in the trial should discuss potential risks and benefits with their healthcare provider.

It’s important to note that ELRAGLUSIB is still in the experimental stage, and its safety and effectiveness have not yet been fully established. The ongoing clinical trial aims to provide more information about this promising new treatment for patients with difficult-to-treat cancers.

Aspect Details
Drug Name Elraglusib (9-ING-41)
Drug Type Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor
Administration Intravenous injection
Target Conditions Refractory hematologic malignancies and solid tumors, specifically metastatic pancreatic cancer
Trial Phase Phase 1/2 integrated clinical trial
Primary Objective Determine 1-year survival rate compared to control arm
Key Secondary Objectives Assess disease control rate, correlate with tumor molecular profiles
Eligibility Adults with confirmed metastatic pancreatic cancer, no prior systemic treatment for advanced disease
Key Endpoints 1-year survival rate, disease control rate, objective response rate, progression-free survival, overall survival

FAQ

  • What is Elraglusib? Elraglusib, also known as 9-ING-41, is an investigational drug that works by inhibiting a protein called Glycogen Synthase Kinase-3 Beta (GSK-3β). It is being studied for the treatment of various types of cancer, including blood cancers and solid tumors.
  • What types of cancer is Elraglusib being tested for? Elraglusib is being tested for refractory hematologic malignancies (blood cancers) and solid tumors. In the current trial, it is specifically being studied for patients with metastatic pancreatic cancer who have not received prior systemic treatment for advanced disease.
  • How is Elraglusib given to patients? Elraglusib is given as an injection, typically through intravenous administration. The exact dosing schedule may vary depending on the specific trial and whether it is given alone or in combination with other chemotherapy drugs.
  • What are the main goals of the Elraglusib clinical trial? The main goals of the trial include determining the 1-year survival rate of patients treated with Elraglusib, assessing the rate of disease control when combined with other chemotherapy drugs, and correlating disease control with tumor molecular profiles.
  • Who is eligible to participate in the Elraglusib clinical trial? Eligible participants include adults (18 years or older) with confirmed metastatic pancreatic cancer who have not received prior systemic treatment for advanced disease. Patients must have measurable tumors, adequate organ function, and meet specific health criteria. Detailed eligibility requirements are determined by the study doctors.

Ongoing Clinical Trials on Elraglusib

  • Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Portugal Spain

Glossary

  • Refractory: A condition that does not respond to standard treatments or when the disease continues to progress despite therapy.
  • Hematologic Malignancies: Cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia, lymphoma, and multiple myeloma.
  • Solid Tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign (not cancer) or malignant (cancer).
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Glycogen Synthase Kinase-3 Beta (GSK-3β): A protein involved in various cellular processes, including cell growth and division. Inhibiting this protein is the mechanism by which Elraglusib may help treat cancer.
  • Disease Control Rate (DCR): The percentage of patients whose cancer shrinks or remains stable for a certain period after treatment.
  • Objective Response Rate (ORR): The proportion of patients whose tumors shrink or disappear after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.

References

  1. http://clinicaltrials.eu/trial/study-of-elraglusib-alone-or-with-chemotherapy-for-patients-with-refractory-blood-cancers-or-solid-tumors/